DYNAMICS OF CHARACTERISTICS OF THE GLYCEMICAL PROFILE OF PATIENTS WITH CORONARY HEART DISEASE AND OBESITY AFTER TREATMENT

Olga V. Gridneva
{"title":"DYNAMICS OF CHARACTERISTICS OF THE GLYCEMICAL PROFILE OF PATIENTS WITH CORONARY HEART DISEASE AND OBESITY AFTER TREATMENT","authors":"Olga V. Gridneva","doi":"10.31612/2616-4868.4(26).2023.04","DOIUrl":null,"url":null,"abstract":"Introduction. Cardiovascular diseases (CVD) have the status of an epidemic, as they have high levels of prevalence and are the main cause of disability and mortality both in Ukraine and in the world and cause a significant increase in health care costs. Among all CVDs, coronary heart disease (CHD) ranks first. Many studies confirm a high percentage of CHD among all CVDs, especially in comorbidity with hyperlipidemia and obesity. Therefore, when treating CHD disease with obesity, it is necessary to take into account the effectiveness of the applied pharmacological agents and determine the dynamics of pharmacological intervention.&#x0D; The aim. To determine the dynamics of indicators of the glycemic profile in the comorbid course of CHD and obesity after the treatment.&#x0D; Materials and methods. It was conducted a randomized controlled single-center prospective study case-control, which is based on the analysis of the results of 130 people aged 25–85 were examined, who were divided into 3 groups: 70 persons (main group) with CHD on the background of obesity and 35 people with isolated coronary artery disease (comparison group) and control group (25 practically healthy people). The studied groups were randomized by age and gender.&#x0D; Results. Before treatment, a probable predominance of daily glucose levels was determined in patients main group to the patients comparison group and controls. According to the results of the glucose tolerance test (GTT), an improbable excess of fasting glucose levels and after a glucose load was determined in CHD with obesity (respectively 5.64±1.92 and 7.08±2.25 mmol/l) compared to the isolated of CHD (respectively 5, 15±2.22 (p=0.791) and 6.20±3.15 (p=0.403) mmol/l) and control group (respectively 5.32±0.49 (p=0.685) and 5.42±0, 51 (p<0.001) mmol/l). After treatment, recovery of blood glucose levels was determined.&#x0D; Conclusions. It was established that the characteristics of the dynamics of glucose metabolism indicators can be used as an indicator of the effectiveness of the treatment in the comorbidity of obesity and CHD. The obtained results indicate that the characteristics of glucose metabolism in the comorbidity of CHD and obesity must be taken into account to ensure therapeutic and preventive measures.","PeriodicalId":34164,"journal":{"name":"Klinichna ta profilaktichna meditsina","volume":"65 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinichna ta profilaktichna meditsina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31612/2616-4868.4(26).2023.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction. Cardiovascular diseases (CVD) have the status of an epidemic, as they have high levels of prevalence and are the main cause of disability and mortality both in Ukraine and in the world and cause a significant increase in health care costs. Among all CVDs, coronary heart disease (CHD) ranks first. Many studies confirm a high percentage of CHD among all CVDs, especially in comorbidity with hyperlipidemia and obesity. Therefore, when treating CHD disease with obesity, it is necessary to take into account the effectiveness of the applied pharmacological agents and determine the dynamics of pharmacological intervention. The aim. To determine the dynamics of indicators of the glycemic profile in the comorbid course of CHD and obesity after the treatment. Materials and methods. It was conducted a randomized controlled single-center prospective study case-control, which is based on the analysis of the results of 130 people aged 25–85 were examined, who were divided into 3 groups: 70 persons (main group) with CHD on the background of obesity and 35 people with isolated coronary artery disease (comparison group) and control group (25 practically healthy people). The studied groups were randomized by age and gender. Results. Before treatment, a probable predominance of daily glucose levels was determined in patients main group to the patients comparison group and controls. According to the results of the glucose tolerance test (GTT), an improbable excess of fasting glucose levels and after a glucose load was determined in CHD with obesity (respectively 5.64±1.92 and 7.08±2.25 mmol/l) compared to the isolated of CHD (respectively 5, 15±2.22 (p=0.791) and 6.20±3.15 (p=0.403) mmol/l) and control group (respectively 5.32±0.49 (p=0.685) and 5.42±0, 51 (p<0.001) mmol/l). After treatment, recovery of blood glucose levels was determined. Conclusions. It was established that the characteristics of the dynamics of glucose metabolism indicators can be used as an indicator of the effectiveness of the treatment in the comorbidity of obesity and CHD. The obtained results indicate that the characteristics of glucose metabolism in the comorbidity of CHD and obesity must be taken into account to ensure therapeutic and preventive measures.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
冠心病合并肥胖患者治疗后血糖特征的动态变化
介绍。心血管疾病具有流行病的地位,因为它们的发病率很高,是乌克兰和世界致残和死亡的主要原因,并导致保健费用大幅增加。在所有心血管疾病中,冠状动脉心脏疾病(CHD)排名第一。许多研究证实,冠心病在所有心血管疾病中所占比例很高,特别是与高脂血症和肥胖合并症。因此,在治疗冠心病合并肥胖时,需要考虑所应用药物的有效性,确定药物干预的动态。 的目标。探讨治疗后冠心病与肥胖共病过程中血糖指标的动态变化。 材料和方法。本研究采用随机对照、单中心前瞻性病例-对照研究方法,在对年龄在25 - 85岁之间的130人进行结果分析的基础上,将其分为3组:肥胖背景的冠心病患者70人(主组)、孤立性冠状动脉疾病患者35人(对照组)和对照组(实际健康人25人)。实验组按年龄和性别随机分组。 结果。在治疗前,确定患者主要组的每日血糖水平可能高于患者对照组和对照组。葡萄糖耐量试验(GTT)结果显示,与冠心病分离组(5.15±2.22 (p=0.791)和6.20±3.15 (p=0.403) mmol/l和对照组(5.32±0.49 (p=0.685)和5.42±0.51 (p= 0.001) mmol/l相比,肥胖冠心病患者空腹血糖水平和葡萄糖负荷后血糖水平分别为5.64±1.92和7.08±2.25 mmol/l)。治疗后测定血糖恢复情况。 结论。建立了糖代谢指标的动态特征可以作为肥胖合并冠心病治疗效果的指标。本研究结果提示,在冠心病合并肥胖的合并症中,必须考虑糖代谢的特点,以确保治疗和预防措施。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
34
审稿时长
12 weeks
期刊最新文献
CORRELATION BETWEEN INDICATORS OF BALANCE OF NERVOUS PROCESSES WITH LOCALIZATION OF CONTROL IN HIGH SKILLED WOMEN HANDBALL PLAYERS QUALITY OF LIFE AND PAIN MANAGEMENT IN PATIENTS AFTER GUNSHOT WOUNDS GUT MICROBIOTA AND CARDIOMETABOLIC RISK FACTORS IN CORONARY ARTERY DISEASE PATIENTS WITH ATRIAL FIBRILLATION THE EFFECTIVENESS OF CORRECTION OF HAND MOTILITY BY MEANS OF PHYSICAL THERAPY, OCCUPATION THERAPY (HAND THERAPY) IN THE REHABILITATION PROCESS OF MILITARY SERVANTS WITH THE CONSEQUENCES OF GUNSHOT POLYSTRUCTURAL FOREARM BONE FRACTURES PREVALENCE OF ANXIETY AND DEPRESSION IN PATIENTS AFTER BRAIN STROKE
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1